The Functional (Non Ulcer) Dyspepsia drugs in development market research report provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Functional (Non Ulcer) Dyspepsia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Functional (Non Ulcer) Dyspepsia by 13 companies/universities/institutes. The top development phase for Functional (Non Ulcer) Dyspepsia is phase i with three drugs in that stage. The Functional (Non Ulcer) Dyspepsia pipeline has eight drugs in development by companies and two by universities/ institutes. Some of the companies in the Functional (Non Ulcer) Dyspepsia pipeline products market are: Faes Farma, Mitsubishi Tanabe Pharma and RaQualia Pharma.

The key targets in the Functional (Non Ulcer) Dyspepsia pipeline products market include Substance P Receptor (Tachykinin Receptor 1 or NK 1 Receptor or NK1R or TACR1), Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19), and Phosphate.

The key mechanisms of action in the Functional (Non Ulcer) Dyspepsia pipeline product include Bile Acid Sequestrant with one drug in Phase II. The Functional (Non Ulcer) Dyspepsia pipeline products include one routes of administration with the top ROA being Oral and two key molecule types in the Functional (Non Ulcer) Dyspepsia pipeline products market including Small Molecule, and Polymer.

Functional (Non Ulcer) Dyspepsia overview

Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called functional dyspepsia or non-ulcer stomach pain. Signs and symptoms include a burning sensation or discomfort in the upper abdomen or lower chest, sometimes relieved by food or antacids; bloating; belching; and nausea. The predisposing factors include excessive consumption of caffeine or alcohol, smoking, and taking certain medications, especially certain over-the-counter pain relievers such as aspirin and ibuprofen (advil, motrin, others), which can cause stomach problems. Treatment includes medications to reduce acid production, antibiotics, and low-dose antidepressants.

For a complete picture of Functional (Non Ulcer) Dyspepsia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.